Contents

Volume 80 Issue 12 | ARD December 2021

Editorial
1503 Towards clinical significance of the MUC5B promoter variant and risk of rheumatoid arthritis-associated interstitial lung disease
J A Sparks

Viewpoint
1505 Nothing about us without us: involving patient collaborators for machine learning applications in rheumatology
S J W Sloggett-Warrall, K G Wassell, J Bolger, B Dillon, K L Hyrich, N Geffman, Members of the CLUSTER consortium

Review
1511 Axial spondyloarthritis
V Navarro-Compan, A Sepulveda, B El-Zorkany, D van der Heijde

Rheumatoid arthritis
1522 Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naïve patients with rheumatoid arthritis
A J Oon, G Reed, D A Pappas, J R Curtis, J M Kremer

1530 Lifetime risk of rheumatoid arthritis-associated interstitial lung disease in MUC5B mutation carriers
A Palomäki, FinnGen Rheumatology Clinical Expert Group, A Palotie, J Koskelä, K K Ekholm, M Pirinen, FinnGen, S Ripatti, T Laitinen, N Mars

1537 B cell depletion impairs vaccination-induced CD8+ T cell responses in a type I interferon-dependent manner
T Graßmann, K Borst, H Marchanda, I Vaas, M Bruhn, L Grassmann, M Kessler, M Verboom, M Hallensleben, C A Guzman, G Sutter, R E Schmidt, T Witt, U Kadinke

Psoriatic arthritis
1553 Role of ultrasound for assessment of psoriatic arthritis patients with fibromyalgia

1559 Ex vivo mass cytometry analysis reveals a profound myeloid proinflammatory signature in psoriatic arthritis synovial fluid
N Yager, S Cole, A Lledo Lara, A Maroof, F Penna, J C Knight, P Bowness, H Al-Mossawi

Systemic lupus erythematosus
1568 Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity
D Jesus, M Larosa, C Henriques, A Matos, M Zen, P Tomé, V Alves, N Costa, V Le Guen, L Iacarino, N Costeboa-Chalumeau, A Doria, L S Inês

1575 Metagenome-wide association study revealed disease-specific landscape of the gut microbiome of systemic lupus erythematosus in Japanese

Inflammatory arthritis
1545 Impaired fertility in men diagnosed with inflammatory arthritis: results of a large multicentre study (IFAME-Fertility)
Systemic sclerosis
1584 Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis
K E N Clark, C Campochiaro, E Caemmer, A Taylor, K Nevin, N Galwey, M A Morse, J Singh, Y V Teo, V H Ong, E Derrett-Smith, N Wisnacki, S M Flint, C R Denton

1594 TGFβ promotes low IL10-producing ILC2 with profibrotic ability involved in skin fibrosis in systemic sclerosis

Crystal arthritis
1604 Mechanosensitive TRPV4 is required for crystal-induced inflammation
Z Lin, L Chen, J Feng, Z Xie, Z Liu, F Wang, P Liu, X Yue, L Du, Y Zhao, P Yang, J Luo, Z Zhu, X Hu, L Cao, P Lu, R Sah, K Lavine, B Kim, H Hu

Osteoarthritis
1615 14-3-3 epsilon is an intracellular component of TNFR2 receptor complex and its activation protects against osteoarthritis
W Fu, A Hettinghouse, Y Chen, W Hu, X Ding, M Chen, Y Ding, M Mundia, W Song, R Liu, Y-S Yu, M Amar, J Samuel, S Strauss, P Leucht, R Schwarzburg, C Liu

Letters
1628 Early reduction in circulating monocyte count predicts maintenance of remission in patients with rheumatoid arthritis treated with anti-TNF therapy
M R A Shipa, R Amarnani, S-A Yeoh, M D Mainuddin, M R Ehrenstein

1629 Nail involvement in psoriatic arthritis patients is an independent risk factor for carotid plaque

1631 Tofacitinib for the treatment of antineutrophil cytoplasm antibody-associated vasculitis: a pilot study
Y Liu, Z Ji, W Yu, S Wu, H Chen, L Ma, Z Ding, L Jiang

1633 Immunotheapies and COVID-19 mortality: a multidisciplinary open data analysis based on FDA’s Adverse Event Reporting System
M Pistor, A G F Hoepner, Y Liu, S Jung, C L Bassetti, A Chau, A Selmen, R Hoepner

1635 Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis
S Bugani, L De Stefano, S Balduzzi, M J Greco, T Luvato, I Cassaniti, I Bogliolo, I Mazzucchelli, B D’Onofrio, M di Lernia, E Mauric, D Lilleri, F Baldoni, A Manzo, C Montecucco

1638 Unexpected impact of COVID-19 lockdown on spinal mobility and health perception in spondyloarthritis
S De Mitis, A-S De Caenier, I Deroo, T Reuson, F E Van den Bosch, P Cartron, D Elewaat

Electronic pages
e188 European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist’s point of view
M Infanteo, M Manfredi, N Bizzarri, On behalf of the Study Group on Autoimmune Diseases of the Italian Society of Clinical Pathology and Laboratory Medicine

e189 Response to: ‘European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist’s point of view’ by Infantino et al
M Aringer, K H Costenbader, T Dörner, S R Johnson

e190 New 2019 SLE EULAR/ACR classification criteria are valid for identifying patients with SLE among patients admitted for pericardial effusion
K Sacre, I Dekaval, A Dossier, J-F Alexandre, M Berfeur, M-P Chauvet, G Ducroq, T Coulon, D van Gysel, D Rouzaud, T Papo

e191 Response to: ‘New 2019 SLE EULAR/ACR classification criteria are valid for identifying patients with SLE among patients admitted for pericardial effusion’ by Sacre et al
M Aringer, K Costenbader, T Dörner, S R Johnson
**Contents**

**Volume 80  Issue 12  | ARD December 2021**

**e192** Development and initial validation of diagnostic gene signatures for systemic lupus erythematosus

B Wang, S Chen, Q Zheng, Z Gao, R Chen, J Xuan, Y Liu, C Shi

**e193** Response to: ‘Development and initial validation of diagnostic gene signatures for systemic lupus erythematosus’ by Wang et al

M Aringer, K Costenbader, T Dörner, S R Johnson

**e194** NCF1-339 polymorphism and systemic lupus erythematosus

B Joob, V Wiwanitkit

**e195** Response to: ‘NCF1-339 polymorphism and systemic lupus erythematosus’ by Joob and Wiwanitkit

C P Linge, A Bengtsson

**e196** Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors

A Meyer, P S Wittekind, K Kotschenreuther, J Schiller, J von Tresckow, T H Haak, D M Kofer

**e197** Response to: ‘Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors’ by Meyer et al

M Rosenzweig, R Lorenzon, D Klattmann

**e198** Correspondence to ‘Slope sign’: a feature of large vessel vasculitis?

M Milchert, M Brezsko, A Bull Haavensen, A P Diamantopoulos

**e199** Response to: ‘Correspondence to ‘Slope sign’: a feature of large vessel vasculitis?’ by Milchert et al

A Sebastian, A Kayani, B Dasgupta

**e200** Clarification regarding the statement of the association between the recombinant zoster vaccine (RZV) and gout flares

A M Didierlaurent, C Dessart, A L Cunningham

**e201** Response to: ‘Clarification regarding the statement of the association between the recombinant zoster vaccine (RZV) and gout flares’ by Didierlaurent et al

C Yokose, H Choi

**e202** Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care

K Parperis

**e203** Response to: ‘Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care’ by Parperis et al

E Reddy, C D Mallen, on behalf of the CONTACT trial authors

**e204** Association between osteoporosis and statins therapy: the story continues

A M Burden, S Weiler

**e205** Response to: ‘Association between osteoporosis and statin therapy: the story continues’ by Burden and Weiler

M Leunzer, C Manzfeld, I Bellach, C Deischinger, J Harreiter, S Thurner, P Klimek, A Kautzky-Willer